Although it is impossible to reconcile all these diverse experimental results, we suspect that the type, dose and mode of administration of the Nlrp3 inhibitor and the age, duration, genetic profile, diet, and type of lipotoxic injury of the experimental NASH mouse model used all likely affect the observed results. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.